CD19 and acute lymphoblastic leukemia: For lymphoid leukemias, monoclonal antibodies such as Tafasitamab (anti-CD19) or BiTEs like blinatumomab (anti-CD19/CD3) may enhance the efficacy of DLI-X against CD19+ B-cell malignancies including ALL or mantle cell lymphoma (148–150).